Using engineered nanoparticles to fight tuberculosis
Nanoparticle-based host-directed therapies for eradication of Mycobacterium tuberculosis
['FUNDING_R01'] · STELLENBOSCH UNIVERSITY · NIH-10815747
This study is looking at how tiny particles can help boost the immune system's ability to fight tuberculosis, especially for people whose immune systems are weaker, by making it easier for immune cells to target and kill the bacteria.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STELLENBOSCH UNIVERSITY (nih funded) |
| Locations | 1 site (Stellenbosch, SOUTH AFRICA) |
| Trial ID | NIH-10815747 on ClinicalTrials.gov |
What this research studies
This research investigates how specially designed nanoparticles can enhance the immune response against Mycobacterium tuberculosis, the bacteria that causes tuberculosis. By mimicking the bacteria's characteristics, these nanoparticles aim to improve the ability of immune cells, specifically macrophages, to kill the bacteria effectively. The study focuses on delivering immunomodulatory signals through these nanoparticles to overcome the challenges posed by drug-resistant strains and bacterial persistence. If successful, this approach could lead to more effective treatments for tuberculosis, especially in patients with compromised immune systems.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those with drug-resistant strains or compromised immune systems.
Not a fit: Patients with non-infectious diseases or those who do not have tuberculosis will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for tuberculosis that is more effective against drug-resistant strains.
How similar studies have performed: Other research has shown promise in using nanoparticle-based therapies for infectious diseases, indicating potential success for this novel approach.
Where this research is happening
Stellenbosch, SOUTH AFRICA
- STELLENBOSCH UNIVERSITY — Stellenbosch, SOUTH AFRICA (ACTIVE)
Researchers
- Principal investigator: SAMPSON, SAMANTHA LEIGH — STELLENBOSCH UNIVERSITY
- Study coordinator: SAMPSON, SAMANTHA LEIGH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: bacteria infection, bacterial disease, Bacterial Infections